Clinical trial
A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19
NCT04365101 is registered in ClinicalTrials.gov with Celularity Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19
- Lead sponsor
- Celularity Incorporated
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- September 2, 2020
- Completion date
- February 15, 2023
- Enrollment
- 7 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
analgesics, anti-infective agents, antimetabolites, antineoplastic, antiviral agents, ards, coronaviridae infections, coronavirus, coronavirus infection, immunologic disease, immunologic factors, lung diseases, nidovirales infections, physiological effects of drugs, pneumonia, pneumonia, viral, respiratory tract disease, respiratory tract infections, rna virus infections, severe acute respiratory syndrome coronavirus 2, virus disease